Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: BNXTF )

0.2200 -0.0264 (-10.71%)
Streaming Delayed Price Updated: 3:52 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,000
Open 0.2200
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.2464
Today's Range 0.2200 - 0.2200
52wk Range 0.1285 - 0.5656
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP
Via ACCESSWIRE
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
Via ACCESSWIRE

Performance

YTD
-44.97%
-44.97%
1 Month
+25.71%
+25.71%
3 Month
+38.63%
+38.63%
6 Month
-2.40%
-2.40%
1 Year
-40.59%
-40.59%

More News

Read More
BioNxt Solutions Announces Development of Sublingual Thin-Film for Semaglutide
Via ACCESSWIRE
BioNxt Announces Enhanced Sublingual Product Development Pipeline with Innovative Solutions for Autoimmune Diseases and Longevity
Via ACCESSWIRE
BioNxt Solutions Announces Closing of Third and Final Tranche of Non-Brokered Private Placement
Via ACCESSWIRE
Terry Lynch Joins BioNxt as Capital Markets Advisor
Via ACCESSWIRE
BioNxt Provides Update on Cladribine Program for Multiple Sclerosis, Sublingual Neurodegenerative Disease Patent, and Investor Relations Activities
Via ACCESSWIRE
BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
Via ACCESSWIRE
BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations
Via ACCESSWIRE
BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development
Via ACCESSWIRE
BioNxt Signs Master Services Agreement with International Contract Research, Development, and Manufacturing Organization
Via ACCESSWIRE
BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps
Via ACCESSWIRE
BioMedNewsBreaks – BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: BNXTF) (FSE: BXT) Announces Highly Promising Results from ODF Cladribine PK Study
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioNxt Reports Successful Results From ODF Cladribine PK Study
Via ACCESSWIRE
BioNxt Reports Successful Results From ODF Cladribine Toxicity Study
Via ACCESSWIRE
BioNxt Receives Delivery of Premium Commercial Coating and Cutting Equipment for Commercial Manufacturing of Drug Delivery Products
Via ACCESSWIRE
BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treament
Via ACCESSWIRE
BioNxt Reports on New Cladrabine ODF Product Development and Commercialization Program
Via ACCESSWIRE
BioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple Sclerosis
Via ACCESSWIRE
BioNxt Signs LOI for Acquisition of IP and Co-Development of ODF Drug Reformulation for Neurodegenerative Disease
Via ACCESSWIRE
BioNxt Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson’s Disease
Via ACCESSWIRE
BioNxt Successfully Completes Pilot Study for Contract Development Customer
Via ACCESSWIRE
BioNxt Secures Contract to Develop and Manufacture ODF Product for International Pharmaceutical Company
Via ACCESSWIRE
BioNxt Acquires Commercial Coating and Cutting Equipment to Build Out European Commercial Manufacturing Capacity
Via ACCESSWIRE
BioNxt Solutions Acquires Novel Precision Drug Coating and Delivery Technology
Via ACCESSWIRE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.